Profile data is unavailable for this security.
About the company
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
- Revenue in USD (TTM)0.00
- Net income in USD-39.98m
- Incorporated2020
- Employees12.00
- LocationDogwood Therapeutics Inc44 Milton AvenueALPHARETTA 30009United StatesUSA
- Websitehttps://dwtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | 58.42m | 2.49m | 82.62m | 213.00 | 35.70 | 19.81 | 20.78 | 1.41 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 84.00m | 31.00 | -- | 15.61 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 84.06m | 44.00 | -- | 1.22 | -- | 29.81 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 84.40m | 19.00 | -- | 4.32 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 87.30m | 56.00 | -- | 1.09 | -- | 459.45 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 88.38m | 42.00 | -- | 4.76 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| Spruce Biosciences Inc | 697.00k | -47.88m | 88.80m | 9.00 | -- | 8.68 | -- | 127.40 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 89.78m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -25.92m | 89.82m | 29.00 | -- | 1,023.54 | -- | -- | -0.2883 | -0.2883 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 90.67m | 67.00 | -- | 2.88 | -- | 129.91 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Incannex Healthcare Inc | 12.00k | -47.87m | 93.13m | 12.00 | -- | 1.21 | -- | 7,761.22 | -0.9375 | -0.9375 | 0.0001 | 0.2215 | 0.0003 | -- | 0.0015 | 1,000.00 | -101.03 | -155.80 | -114.13 | -186.20 | -- | -- | -398,933.30 | -6,230.96 | -- | -43.84 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 93.80m | 4.00 | -- | 6.12 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 94.45m | 25.00 | -- | 2.59 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Equillium Inc | 4.39m | -24.42m | 97.43m | 35.00 | -- | 3.14 | -- | 22.18 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 97.93m | 106.00 | -- | 0.7579 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Actuate Therapeutics Inc | 0.00 | -24.12m | 98.55m | 10.00 | -- | 9.01 | -- | -- | -1.19 | -1.19 | 0.00 | 0.4705 | 0.00 | -- | -- | 0.00 | -150.86 | -- | -282.00 | -- | -- | -- | -- | -- | -- | -- | 0.0357 | -- | -- | -- | -10.27 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Dogwood Therapeutics Inc's reporting currency: US Dollar USD
2.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 18.49k | 0.97% |
| Geode Capital Management LLCas of 30 Sep 2025 | 15.08k | 0.79% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 11.46k | 0.60% |
| UBS Securities LLCas of 31 Dec 2025 | 1.75k | 0.09% |
| Tower Research Capital LLCas of 30 Sep 2025 | 744.00 | 0.04% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 600.00 | 0.03% |
| Activest Wealth Management LLCas of 31 Dec 2025 | 120.00 | 0.01% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2025 | 99.00 | 0.01% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 30.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 14.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
